Leptin in congenital and HIV-associated lipodystrophy

Metabolism: Clinical and Experimental

Volumn 64, Issue 1, 2015, Pages 47-59

  Tsoukas, Michael A ^a   Farr, Olivia M ^a   Mantzoros, Christos S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Congenital lipodystrophy; HIV associated lipodystrophy; Leptin; Metabolism

Indexed keywords

ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; DARUNAVIR; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; GONADORELIN AGONIST; INDINAVIR; LAMIVUDINE; LEPTIN; LOPINAVIR; MARAVIROC; METFORMIN; METRELEPTIN; NEVIRAPINE; PIOGLITAZONE; RALTEGRAVIR; RECOMBINANT GROWTH HORMONE; RECOMBINANT LEPTIN; RILPIVIRINE; RITONAVIR; ROSIGLITAZONE; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ADIPOGENESIS; ADIPOSE TISSUE; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL GENERALIZED LIPODYSTROPHY; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; FATIGUE; FATTY ACID OXIDATION; FATTY LIVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LEPTIN DEFICIENCY; METABOLIC DISORDER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIDE EFFECT; WEIGHT REDUCTION; ANIMAL; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; LIPODYSTROPHY; METABOLIC DISEASES; METABOLISM;

ANIMALS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LEPTIN; LIPODYSTROPHY; METABOLIC DISEASES;

EID: 84921953911     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.07.017     Document Type: Review

References (153)

1. E.E. Kershaw, and J.S. Flier Adipose tissue as an endocrine organ J Clin Endocrinol Metab 89 6 2004 2548 2556
2. J.K. Kim, O. Gavrilova, and Y. Chen Mechanism of insulin resistance in a-zip/f-1 fatless mice J Biol Chem 275 12 2000 8456 8460
3. R.B. Ceddia Direct metabolic regulation in skeletal muscle and fat tissue by leptin: implications for glucose and fatty acids homeostasis Int J Obes (Lond) 29 10 2005 1175 1183
4. C.S. Mantzoros, F. Magkos, and M. Brinkoetter Leptin in human physiology and pathophysiology Am J Physiol Endocrinol Metab 301 4 2011 E567 E584
5. M. Rosenbaum, M. Sy, and K. Pavlovich Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli J Clin Invest 118 7 2008 2583 2591
6. I.S. Farooqi, E. Bullmore, and J. Keogh Leptin regulates striatal regions and human eating behavior Science 317 5843 2007 1355
7. H.R. Kissileff, J.C. Thornton, and M.I. Torres Leptin reverses declines in satiation in weight-reduced obese humans Am J Clin Nutr 95 2 2012 309 317
8. W. Hinkle, M. Cordell, and R. Leibel Effects of reduced weight maintenance and leptin repletion on functional connectivity of the hypothalamus in obese humans PLoS One 8 3 2013 e59114
9. S. Bluher, and C.S. Mantzoros Leptin in humans: lessons from translational research Am J Clin Nutr 89 3 2009 991s 997s
10. X. Prieur, Y.C. Tung, and J.L. Griffin Leptin regulates peripheral lipid metabolism primarily through central effects on food intake Endocrinology 149 11 2008 5432 5439
11. C.S. Mantzoros, R.C. Frederich, and D. Qu Severe leptin resistance in brown fat-deficient uncoupling protein promoter-driven diphtheria toxin a mice despite suppression of hypothalamic neuropeptide y and circulating corticosterone concentrations Diabetes 47 2 1998 230 238
12. Y. Minokoshi, and B.B. Kahn Role of amp-activated protein kinase in leptin-induced fatty acid oxidation in muscle Biochem Soc Trans 31 Pt 1 2003 196 201
13. H.S. Moon, M. Dalamaga, and S.Y. Kim Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals Endocr Rev 34 3 2013 377 412
14. M. Brinkoetter, F. Magkos, and M. Vamvini Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women Am J Physiol Endocrinol Metab 301 1 2011 e99 e104
15. T. Kelesidis, I. Kelesidis, and S. Chou Narrative review: the role of leptin in human physiology: emerging clinical applications Ann Intern Med 152 2 2010 93 100
16. J.L. Chan, S. Bluher, and N. Yiannakouris Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans Diabetes 51 7 2002 2105 2112
17. I.S. Farooqi, G. Matarese, and G.M. Lord Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency J Clin Invest 110 8 2002 1093 1103
18. S. Bluher, and C.S. Mantzoros Leptin in reproduction Curr Opin Endocrinol Diabetes Obes 14 6 2007 458 464
19. S.A. Shea, M.F. Hilton, and C. Orlova Independent circadian and sleep/wake regulation of adipokines and glucose in humans J Clin Endocrinol Metab 90 5 2005 2537 2544
20. C.S. Mantzoros, A. Varvarigou, and V.G. Kaklamani Effect of birth weight and maternal smoking on cord blood leptin concentrations of full-term and preterm newborns J Clin Endocrinol Metab 82 9 1997 2856 2861
21. L. Audi, C.S. Mantzoros, and A. Vidal-Puig Leptin in relation to resumption of menses in women with anorexia nervosa Mol Psychiatry 3 6 1998 544 547
22. K.L. Houseknecht, C.S. Mantzoros, and R. Kuliawat Evidence for leptin binding to proteins in serum of rodents and humans: modulation with obesity Diabetes 45 11 1996 1638 1643
23. D.D. Pierroz, M. Ziotopoulou, and L. Ungsunan Effects of acute and chronic administration of the melanocortin agonist mtii in mice with diet-induced obesity Diabetes 51 5 2002 1337 1345
24. J.L. Chan, and C.S. Mantzoros Leptin and the hypothalamic-pituitary regulation of the gonadotropin-gonadal axis Pituitary 4 1-2 2001 87 92
25. T.A. Dardeno, S.H. Chou, and H.S. Moon Leptin in human physiology and therapeutics Front Neuroendocrinol 31 3 2010 377 393
26. M.A. Pelleymounter, M.J. Cullen, and M.B. Baker Effects of the obese gene product on body weight regulation in ob/ob mice Science 269 5223 1995 540 543
27. J.L. Halaas, K.S. Gajiwala, and M. Maffei Weight-reducing effects of the plasma protein encoded by the obese gene Science 269 5223 1995 543 546
28. L.A. Campfield, F.J. Smith, and Y. Guisez Recombinant mouse ob protein: evidence for a peripheral signal linking adiposity and central neural networks Science 269 5223 1995 546 549
29. J.L. Chan, and C.S. Mantzoros Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa Lancet 366 9479 2005 74 85
30. G.S. Nagy, S. Tsiodras, and L.D. Martin Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin Clin Infect Dis 36 6 2003 795 802
31. E.A. Oral, V. Simha, and E. Ruiz Leptin-replacement therapy for lipodystrophy N Engl J Med 346 8 2002 570 578
32. E.D. Javor, E.K. Cochran, and C. Musso Long-term efficacy of leptin replacement in patients with generalized lipodystrophy Diabetes 54 7 2005 1994 2002
33. J.H. Lee, J.L. Chan, and E. Sourlas Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy J Clin Endocrinol Metab 91 7 2006 2605 2611
34. H.S. Moon, J.P. Chamberland, and K.N. Diakopoulos Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans Diabetes Care 34 1 2011 132 138
35. J. Yao, W. Yu, and T. Li The pilot study of DXA assessment in Chinese HIV-infected men with clinical lipodystrophy J Clin Densitom 14 1 2011 58 62
36. J.P. Bastard, M. Caron, and H. Vidal Association between altered expression of adipogenic factor srebp1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance Lancet 359 9311 2002 1026 1031
37. M.L. Reitman, E. Arioglu, and O. Gavrilova Lipoatrophy revisited Trends Endocrinol Metab 11 10 2000 410 416
38. P. Domingo, X. Matias-Guiu, and R.M. Pujol Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy AIDS 13 16 1999 2261 2267
39. C.S. Mantzoros Whither recombinant human leptin treatment for HIV-associated lipoatrophy and the metabolic syndrome? J Clin Endocrinol Metab 94 4 2009 1089 1091
40. J.L. Chan, and E.A. Oral Clinical classification and treatment of congenital and acquired lipodystrophy Endocr Pract 16 2 2010 310 323
41. A. Garg, and A. Misra Lipodystrophies: rare disorders causing metabolic syndrome Endocrinol Metab Clin North Am 33 2 2004 305 331
42. L. Van Maldergem, J. Magre, and T.E. Khallouf Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy J Med Genet 39 10 2002 722 733
43. A.K. Agarwal, V. Simha, and E.A. Oral Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy J Clin Endocrinol Metab 88 10 2003 4840 4847
44. A. Garg, and A.K. Agarwal Lipodystrophies: disorders of adipose tissue biology Biochim Biophys Acta 1791 6 2009 507 513
45. A. Garg, J.L. Fleckenstein, and R.M. Peshock Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy J Clin Endocrinol Metab 75 2 1992 358 361
46. V. Simha, and A. Garg Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the agpat2 or seipin genes J Clin Endocrinol Metab 88 11 2003 5433 5437
47. W.A. Haque, I. Shimomura, and Y. Matsuzawa Serum adiponectin and leptin levels in patients with lipodystrophies J Clin Endocrinol Metab 87 5 2002 2395
48. V. Simha, A.K. Agarwal, and P.A. Aronin Novel subtype of congenital generalized lipodystrophy associated with muscular weakness and cervical spine instability Am J Med Genet A 146a 18 2008 2318 2326
49. J.D. Brunzell, S.W. Shankle, and J.E. Bethune Congenital generalized lipodystrophy accompanied by cystic angiomatosis Ann Intern Med 69 3 1968 501 516
50. J.L. Fleckenstein, A. Garg, and F.J. Bonte The skeleton in congenital, generalized lipodystrophy: evaluation using whole-body radiographic surveys, magnetic resonance imaging and technetium-99 m bone scintigraphy Skeletal Radiol 21 6 1992 381 386
51. J.R. Guell-Gonzalez, O. Mateo de Acosta, and E. Alavez-Martin Bone lesions in congenital generalised lipodystrophy Lancet 2 7715 1971 104 105
52. S. Bhayana, V.M. Siu, and G.I. Joubert Cardiomyopathy in congenital complete lipodystrophy Clin Genet 61 4 2002 283 287
53. P.G. Bjornstad, A. Foerster, and H. Ihlen Cardiac findings in generalized lipodystrophy Acta Paediatr Suppl 413 1996 39 43
54. K.S. Rheuban, R.M. Blizzard, and M.A. Parker Hypertrophic cardiomyopathy in total lipodystrophy J Pediatr 109 2 1986 301 302
55. S. Tsiodras, C. Mantzoros, and S. Hammer Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study Arch Intern Med 160 13 2000 2050 2056
56. M.K. Leow, C.L. Addy, and C.S. Mantzoros Clinical review 159: human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies J Clin Endocrinol Metab 88 5 2003 1961 1976
57. A. Carr, K. Samaras, and A. Thorisdottir Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study Lancet 353 9170 1999 2093 2099
58. C. Gervasoni, A.L. Ridolfo, and G. Trifiro Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy AIDS 13 4 1999 465 471
59. J.C. Shlay, S. Sharma, and G. Peng The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy J Acquir Immune Defic Syndr 51 3 2009 298 304
60. J. Oh, and R.A. Hegele Hiv-associated dyslipidaemia: pathogenesis and treatment Lancet Infect Dis 7 12 2007 787 796
61. P. Maggi, G. Serio, and G. Epifani Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors AIDS 14 16 2000 F123 F128
62. M. Depairon, S. Chessex, and P. Sudre Premature atherosclerosis in HIV-infected individuals - focus on protease inhibitor therapy AIDS 15 3 2001 329 334
63. J.H. Stein, M.A. Klein, and J.L. Bellehumeur Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction Circulation 104 3 2001 257 262
64. E. Seminari, A. Pan, and G. Voltini Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors Atherosclerosis 162 2 2002 433 438
65. V.A. Triant, H. Lee, and C. Hadigan Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease J Clin Endocrinol Metab 92 7 2007 2506 2512
66. S.W. Worm, C. Sabin, and R. Weber Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (d:A:D) study J Infect Dis 201 3 2010 318 330
67. G. Moyle, and A. Carr Hiv-associated lipodystrophy, metabolic complications, and antiretroviral toxicities HIV Clin Trials 3 1 2002 89 98
68. S. Grinspoon, and A. Carr Cardiovascular risk and body-fat abnormalities in HIV-infected adults N Engl J Med 352 1 2005 48 62
69. T.T. Brown, S.R. Cole, and X. Li Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study Arch Intern Med 165 10 2005 1179 1184
70. T.T. Brown, X. Li, and S.R. Cole Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the multicenter AIDS cohort study AIDS 19 13 2005 1375 1383
71. L.L. Sweeney, A.M. Brennan, and C.S. Mantzoros The role of adipokines in relation to HIV lipodystrophy AIDS 21 8 2007 895 904
72. C. Hadigan, S. Borgonha, and J. Rabe Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy Metabolism 51 9 2002 1143 1147
73. S. Tsiodras, and C. Mantzoros Leptin and adiponectin in the HIV associated metabolic syndrome: physiologic and therapeutic implications Am J Infect Dis 2 3 2006 141 152
74. F. Villarroya, P. Domingo, and M. Giralt Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment Biochim Biophys Acta 1801 3 2010 392 399
75. F. Magkos, and C.S. Mantzoros Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment Metabolism 60 6 2011 749 753
76. J.E. Mallewa, E. Wilkins, and J. Vilar Hiv-associated lipodystrophy a review of underlying mechanisms and therapeutic options J Antimicrob Chemother 62 4 2008 648 660
77. K. El Hadri, M. Glorian, and C. Monsempes In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3 t3 and human preadipocytes or adipocytes J Biol Chem 279 15 2004 15130 15141
78. J.A. Perez-Molina, P. Domingo, and E. Martinez The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy J Antimicrob Chemother 62 2 2008 234 245
79. R.H. Haubrich, S.A. Riddler, and A.G. DiRienzo Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment AIDS 23 9 2009 1109 1118
80. A. Blas-Garcia, N. Apostolova, and D. Ballesteros Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells Hepatology 52 1 2010 115 125
81. J. Chaparro, D.N. Reeds, and W. Wen Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy Metabolism 54 5 2005 561 567
82. C.G. Fiorenza, S.H. Chou, and C.S. Mantzoros Lipodystrophy: pathophysiology and advances in treatment Nat Rev Endocrinol 7 3 2011 137 150
83. S. Shrivastav, T. Kino, and T. Cunningham Human immunodeficiency virus (HIV)-1 viral protein r suppresses transcriptional activity of peroxisome proliferator-activated receptor {gamma} and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy Mol Endocrinol 22 2 2008 234 247
84. M. Duong, J.M. Petit, and L. Piroth Association between insulin resistance and hepatitis c virus chronic infection in HIV-hepatitis c virus-coinfected patients undergoing antiretroviral therapy J Acquir Immune Defic Syndr 27 3 2001 245 250
85. S.H. Han, B.S. Chin, and H.S. Lee Serum retinol-binding protein 4 correlates with obesity, insulin resistance, and dyslipidemia in HIV-infected subjects receiving highly active antiretroviral therapy Metabolism 58 11 2009 1523 1529
86. O.M. Adeyemi, S. Vibhakar, and A.T. Evans Obesity and lymphocyte subsets in virologically suppressed HIV-infected patients Metabolism 58 9 2009 1285 1287
87. R. Rossi, A. Nuzzo, and G. Guaraldi Metabolic disorders induced by highly active antiretroviral therapy and their relationship with vascular remodeling of the brachial artery in a population of HIV-infected patients Metabolism 58 7 2009 927 933
88. S.B. Haugaard, O. Andersen, and S.B. Pedersen Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy Metabolism 55 2 2006 175 182
89. D.L. Jacobson, T. Knox, and D. Spiegelman Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women Clin Infect Dis 40 12 2005 1837 1845
90. A. Gavrila, S. Tsiodras, and J. Doweiko Exercise and vitamin e intake are independently associated with metabolic abnormalities in human immunodeficiency virus-positive subjects: a cross-sectional study Clin Infect Dis 36 12 2003 1593 1601
91. R.M. Blumer, M.G. van Vonderen, and J. Sutinen Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy AIDS 22 2 2008 227 236
92. Y. Minokoshi, Y.B. Kim, and O.D. Peroni Leptin stimulates fatty-acid oxidation by activating amp-activated protein kinase Nature 415 6869 2002 339 343
93. M.Y. Wang, L. Chen, and G.O. Clark Leptin therapy in insulin-deficient type I diabetes Proc Natl Acad Sci U S A 107 11 2010 4813 4819
94. K. Reue, and M. Peterfy Mouse models of lipodystrophy Curr Atheroscler Rep 2 5 2000 390 396
95. I. Shimomura, R.E. Hammer, and S. Ikemoto Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy Nature 401 6748 1999 73 76
96. O. Gavrilova, B. Marcus-Samuels, and L.R. Leon Leptin and diabetes in lipoatrophic mice Nature 403 6772 2000 850 [discussion -1]
97. K. Ebihara, Y. Ogawa, and H. Masuzaki Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes Diabetes 50 6 2001 1440 1448
98. J.M. Guettier, J.Y. Park, and E.K. Cochran Leptin therapy for partial lipodystrophy linked to a ppar-gamma mutation Clin Endocrinol (Oxf) 68 4 2008 547 554
99. J.Y. Park, E.D. Javor, and E.K. Cochran Long-term efficacy of leptin replacement in patients with dunnigan-type familial partial lipodystrophy Metabolism 56 4 2007 508 516
100. E. Asilmaz, P. Cohen, and M. Miyazaki Site and mechanism of leptin action in a rodent form of congenital lipodystrophy J Clin Invest 113 3 2004 414 424
101. K.F. Petersen, E.A. Oral, and S. Dufour Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy J Clin Invest 109 10 2002 1345 1350
102. K. Ebihara, H. Masuzaki, and K. Nakao Long-term leptin-replacement therapy for lipoatrophic diabetes N Engl J Med 351 6 2004 615 616
103. E.D. Javor, M.G. Ghany, and E.K. Cochran Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy Hepatology 41 4 2005 753 760
104. K. Ebihara, T. Kusakabe, and M. Hirata Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy J Clin Endocrinol Metab 92 2 2007 532 541
105. E.A. Oral, and J.L. Chan Rationale for leptin-replacement therapy for severe lipodystrophy Endocr Pract 16 2 2010 324 333
106. S. Park, S.M. Hong, and S.R. Sung Long-term effects of central leptin and resistin on body weight, insulin resistance, and beta-cell function and mass by the modulation of hypothalamic leptin and insulin signaling Endocrinology 149 2 2008 445 454
107. K. Maedler, F.T. Schulthess, and C. Bielman Glucose and leptin induce apoptosis in human beta-cells and impair glucose-stimulated insulin secretion through activation of c-jun n-terminal kinases FASEB J 22 6 2008 1905 1913
108. N.A. Tritos, and C.S. Mantzoros Clinical review 97: syndromes of severe insulin resistance J Clin Endocrinol Metab 83 9 1998 3025 3030
109. V. Simha, L.S. Szczepaniak, and A.J. Wagner Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy Diabetes Care 26 1 2003 30 35
110. A.Y. Chong, B.C. Lupsa, and E.K. Cochran Efficacy of leptin therapy in the different forms of human lipodystrophy Diabetologia 53 1 2010 27 35
111. J.R. McDuffie, P.A. Riggs, and K.A. Calis Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency J Clin Endocrinol Metab 89 9 2004 4258 4263
112. S.A. Moran, N. Patten, and J.R. Young Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy Metabolism 53 4 2004 513 519
113. J.L. Chan, K. Lutz, and E. Cochran Clinical effects of long-term metreleptin treatment in patients with lipodystrophy Endocr Pract 17 6 2011 922 932
114. K. Mulligan, H. Khatami, and J.M. Schwarz The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia J Clin Endocrinol Metab 94 4 2009 1137 1144
115. J. Lo, S.M. You, and B. Canavan Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial JAMA 300 5 2008 509 519
116. L. Luzi, E. Meneghini, and S. Oggionni Gh treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study Eur J Endocrinol 153 6 2005 781 789
117. E.D. Javor, S.A. Moran, and J.R. Young Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy J Clin Endocrinol Metab 89 7 2004 3199 3207
118. D.B. Savage, and S. O'Rahilly Leptin therapy in lipodystrophy Diabetologia 53 1 2010 7 9
119. M.Y. Donath, J.A. Ehses, and K. Maedler Mechanisms of beta-cell death in type 2 diabetes Diabetes 54 Suppl 2 2005 S108 S113
120. M.A. Noor, T. Seneviratne, and F.T. Aweeka Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study AIDS 16 5 2002 F1 F8
121. S.B. Heymsfield, A.S. Greenberg, and K. Fujioka Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial JAMA 282 16 1999 1568 1575
122. R.V. Sekhar, F. Jahoor, and D. Iyer Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome Metabolism 61 10 2012 1395 1403
123. M.A. Tsoukas, O.M. Farr, and C.S. Mantzoros Advances in metabolism Metabolism 62 12 2013 1700 1713
124. A.M. Brennan, J.H. Lee, and S. Tsiodras R-methuleptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating igf and igf-binding protein levels: observational and interventional studies in humans Eur J Endocrinol 160 2 2009 173 176
125. J.L. Chan, G. Matarese, and G.K. Shetty Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans Proc Natl Acad Sci U S A 103 22 2006 8481 8486
126. J.M. Friedman, and J.L. Halaas Leptin and the regulation of body weight in mammals Nature 395 6704 1998 763 770
127. M.N. Rao, K. Mulligan, and V. Tai Effects of insulin-like growth factor (IGF)-i/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance J Clin Endocrinol Metab 95 9 2010 4361 4366
128. C. Wanke, J. Gerrior, and J. Kantaros Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV AIDS 13 15 1999 2099 2103
129. C. Musso, E. Cochran, and E. Javor The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients Metabolism 54 2 2005 255 263
130. E.A. Oral, E. Ruiz, and A. Andewelt Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy J Clin Endocrinol Metab 87 7 2002 3110 3117
131. V. Simha, J.E. Zerwekh, and K. Sakhaee Effect of subcutaneous leptin replacement therapy on bone metabolism in patients with generalized lipodystrophy J Clin Endocrinol Metab 87 11 2002 4942 4945
132. K. Chou, and C.M. Perry Metreleptin: first global approval Drugs 73 9 2013 989 997
133. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm387060.htm Fda announcement 2014
134. T.T. Brown Approach to the human immunodeficiency virus-infected patient with lipodystrophy J Clin Endocrinol Metab 93 8 2008 2937 2945
135. J.A. Aberg Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review Top HIV Med 14 4 2006 134 139
136. M. Aboud, A. Elgalib, and R. Kulasegaram Insulin resistance and HIV infection: a review Int J Clin Pract 61 3 2007 463 472
137. R. Kohli, A. Shevitz, and S. Gorbach A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy HIV Med 8 7 2007 420 426
138. K. Mulligan, Y. Yang, and D.A. Wininger Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio AIDS 21 1 2007 47 57
139. C. Hadigan, S. Yawetz, and A. Thomas Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial Ann Intern Med 140 10 2004 786 794
140. J.P. van Wijk, E.J. de Koning, and M.C. Cabezas Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial Ann Intern Med 143 5 2005 337 346
141. R.B. Cavalcanti, J. Raboud, and S. Shen A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy J Infect Dis 195 12 2007 1754 1761
142. A. Carr, C. Workman, and D. Carey No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial Lancet 363 9407 2004 429 438
143. D.C. Macallan, C. Baldwin, and S. Mandalia Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone HIV Clin Trials 9 4 2008 254 268
144. K.W. Johns, M.T. Bennett, and G.P. Bondy Are HIV positive patients resistant to statin therapy? Lipids Health Dis 6 2007 27
145. J.G. Gerber, S.L. Rosenkranz, and C.J. Fichtenbaum Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study J Acquir Immune Defic Syndr 39 3 2005 307 312
146. V.P. Andreev, G. Paz-Filho, and M.L. Wong Deconvolution of insulin secretion, insulin hepatic extraction post-hepatic delivery rates and sensitivity during 24-hour standardized meals: time course of glucose homeostasis in leptin replacement treatment Horm Metab Res 41 2 2009 142 151
147. C. Hadigan, J. Liebau, and M. Torriani Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia J Clin Endocrinol Metab 91 11 2006 4438 4444
148. D.A. Wohl, H.C. Tien, and M. Busby Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia Clin Infect Dis 41 10 2005 1498 1504
149. M. Bickel, S. Zangos, and V. Jacobi A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy HIV Med 7 6 2006 397 403
150. C. Grunfeld, M. Thompson, and S.J. Brown Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy J Acquir Immune Defic Syndr 45 3 2007 286 297
151. Q. He, E.S. Engelson, and J.B. Albu Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy J Appl Physiol 94 5 2003 2051 2057
152. P. Koutkia, B. Canavan, and J. Breu Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial JAMA 292 2 2004 210 218
153. J. Falutz, S. Allas, and J.C. Mamputu Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation AIDS 22 14 2008 1719 1728